Denali Therapeutics Inc.

Quick facts

Marketed products

• AVLAYAH · Other

Phase 2 pipeline

• DNL343 · Neurology
  DNL343 is a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neurodegeneration.

Phase 1 pipeline

• [14C]-DNL343
• DNL126
• DNL151
• DNL201
• DNL593
• DNL628
• DNL919
• DNL952

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Denali Therapeutics Inc. portfolio CI brief
• Denali Therapeutics Inc. pipeline updates RSS